The global spirometer market size was USD 1,221 million in 2021, which is expected to grow to USD 1,608 million with a CAGR of 3.5% during the forecast period (2022-2030).
A spirometer is a device that analyses the volume of air breathed and expelled during a single breathing cycle. The gadget aids in diagnosing various respiratory disorders, such as chronic obstructive pulmonary disease, emphysema, asthma, and other respiratory diseases, for occupational screening purposes. Spirometers are among the most frequent instruments seen in respiratory laboratories and clinics. Spirometers can generate a user's lung health profile. Consequently, clinicians utilize spirometers as both a diagnostic and monitoring tool. Personalized spirometers for patient usage outside of the clinic provide numerous advantages. Regular spirometry can detect a loss in lung health or a worsening disease development much earlier. This allows the patient and physician to avoid and treat the problem before its deterioration.
The increased incidence of chronic obstructive pulmonary disease (COPD) worldwide ultimately drives up demand for spirometers. The World Health Organization stated that around 300 million people worldwide have asthma, and 250,000 have died. In 2019, around 65 million individuals worldwide had COPD, including approximately 16 million Americans, which is expected to increase. In addition, chronic obstructive pulmonary disease is one of the primary causes of morbidity and mortality nationwide, and various studies have demonstrated that the general community is primarily unaware of COPD. However, many people with respiratory symptoms are unaware that they need to be diagnosed, which restricts the usage of spirometers for detecting respiratory devices.
|Market Size||USD 1,608 million by 2030|
|Fastest Growing Market||Asia Pacific|
|Largest Market||North America|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
Globally, respiratory disorders are among the primary causes of mortality and disability. Several factors contribute to the rise in the prevalence of respiratory disorders in the population, including unhealthy air, outdoor and indoor pollution, tobacco use through smoking, and harmful particles emitted at workplaces. In the past few years, there has been a significant increase in cases resulting in respiratory failure and mortality. In 2017, according to the WHO, approximately 65 million people suffered from chronic obstructive pulmonary disease, and approximately 3 million died annually. Asthma is the most common pediatric chronic condition, affecting 14% of children worldwide. It affects almost 334 million individuals. As effective healthcare solutions, such as spirometers, are available, improving respiratory health by early identification and diagnosis can prevent, control, and cure many disorders.
Consequently, as respiratory disorders become more prevalent, the global spirometer market is anticipated to experience tremendous expansion in the coming years. In addition, spirometers can detect chemical exposure in the workplace, shortness of breath, drug side effects, lung performance assessment before surgery, and illness treatment progress. Thus, such benefits of spirometers are anticipated to contribute to the expansion of the global market.
In addition, lifestyle habits such as smoking and alcohol consumption that lead to respiratory problems are one of the primary factors driving the expansion of the global spirometer market. As spirometers aid in the early detection of several respiratory ailments, the prevalence of these diseases is expected to increase, hence driving up demand. In addition, an increase in the elderly population, prone to various respiratory illnesses, drives the spirometer market expansion. Moreover, technological advancements in spirometry and an increase in regulatory approvals contribute to the expansion of the global market.
In most poor and underdeveloped regions, respiratory disease sufferers are prevalent. In 2017, the Global Burden of Disease Study stated that there were 251 million cases of COPD worldwide, with over 90% of COPD deaths occurring in low- and middle-income countries. In developing nations, a rise in the prevalence of respiratory disorders has been primarily attributed to a lack of disease knowledge.
Furthermore, industrialized nations such as the United Kingdom and the United States have reported comparable levels of respiratory disease awareness. In the past few years, these nations have been plagued by a widespread late diagnosis of COPD among individuals. Despite several awareness initiatives and events, over 1,2 million people in the United Kingdom live with COPD. Thus, creating restraint in the global spirometer market expansion.
During the unprecedented epidemic, individuals favored home healthcare options over hospital or clinic care. This offered significant potential for industry leaders to meet the people's demands by creating tiny, portable, and easy-to-use spirometers for at-home pulmonary function testing. In addition, the introduction of tele-spirometers is a consequence of the growing popularity of home care settings. In addition, the elderly are more prone to a variety of respiratory disorders and require specialized and accommodating healthcare services.
This ultimately increases the need for more healthcare employees, resulting in a scarcity of personnel in the medical industry. On the other hand, because the elderly are less mobile, it is more convenient for them to receive treatment at home than travel to a healthcare facility. Consequently, the growing desire for spirometers in-home healthcare due to patients' value-based care at home is predicted to create lucrative prospects for companies operating in the spirometer market.
North America will command the market with the largest share and a CAGR of 3.2% during the forecast period. Rising asthma, COPD, and cystic fibrosis rates are primarily responsible for the region's predominance. Based on the data provided by the American Lung Association, COPD is the third largest cause of death in the United States. Additionally, roughly 20.4 million persons have asthma in the United States. Hence, there is a rising preference for pulmonary function testing among Americans and physicians for early diagnosis of lung disorders to avoid exorbitant medical bills in the future. In addition, technological improvements for manufacturing user-friendly and portable spirometers and increased patient awareness are anticipated to drive spirometer market expansion in the U.S. over the projection period.
Additionally, North America is regarded as early adoption of modern medical advances. This is primarily attributable to increased awareness of the various respiratory therapies offered in hospitals and the expansion of government and NGO programs. Thus, it is anticipated that the need for spirometers will increase among people suffering from various respiratory disorders.
Asia-Pacific will hold the second-largest share of USD 539 million with a CAGR of 4.5%. Due to its vast population base, numerous chronic and lifestyle disorders, and rapid rise in the prevalence of respiratory diseases, the Asia-Pacific market offers the lucrative potential to participants in the spirometer industry. During the projected period, the market for spirometers is anticipated to be propelled by a rise in the proportion of geriatric patients sensitive to a variety of respiratory diseases, as well as a rise in spirometer usage in general healthcare settings such as hospitals. In addition, using artificial intelligence (AI) in spirometers is anticipated to generate potential prospects for key market participants.
Increasing demand for advanced medical devices, healthcare reforms, and the incidence of chronic respiratory disorders such as asthma, COPD, cystic, and pulmonary fibrosis all contribute to spirometer market expansion. In addition, an increase in programs, grants, and projects on the accessibility of medical equipment in the region is predicted to drive the spirometer market expansion further.
Based on type, the market segmentation includes hand-held and table-top.
Table-top is expected to hold the largest market share with a CAGR of 3.7% during the forecast period. This is mainly attributable to its ability to produce accurate results and the increasing number of deployments in hospitals, clinics, and laboratories. These devices can provide precise measurements and conduct systematic testing on tidal spirometry, flow volume, and maximum voluntary breathing. However, table-top spirometers are expensive and can only be handled by qualified specialists. In addition, data calculations can be automated, the subject can breathe fresh air during the test, and there are no moving parts, which increases the accuracy of the results.
Hand-held spirometers are generally either tiny desktop equipment or portable home-use devices. In addition, they are compact, lightweight, and have a low power consumption. In addition, technological developments in these spirometers, such as improved graphic display, wireless connectivity, and accuracy of readings, will likely increase their popularity in the coming years.
Based on technology, the market segmentation includes volume measurement and flow measurement.
The flow measurement segment grow with the highest CAGR of 4.1% during the forecast period. These spirometers are equipped with sensors, microprocessors, and software for calculating air flow rates and determining whether a patient's lungs have airway obstruction. These spirometers are tiny, portable, automated, and aid in decreasing test-related illnesses. Consequently, they are more preferred than spirometers with volume measurement technology and are anticipated to experience to expand further during the forecast period.
Volume measurement technology-equipped spirometers measure exhaled air volumes directly and typically contain no air before testing begins. This permits patients to directly inhale and exhale into a spirometer, i.e., in a closed-circuit breathing system. These devices are less expensive and easier to operate than flow measurement equipment. Nevertheless, one of the significant drawbacks of the volume measurement technique in spirometers is that the instrument might develop leaks with time. This can lead to inaccurate air volume measurements and ultimately to incorrect readings. In addition, spirometers using volume measurement technology are huge and cumbersome, less portable, and may be susceptible to infection.
The market segmentation includes COPD, asthma, and other applications based on application.
COPD or Chronic obstructive pulmonary disease is expected to hold the largest share growing with a CAGR of 4.1% during the forecast period. Chronic obstructive pulmonary disease encompasses a range of disorders that impede lung airflow and create breathing-related issues. Included among these are emphysema and chronic bronchitis. For a couple of decades, spirometers have been the most popular tool for early diagnosis of COPD among the general population, which is expected to increase demand for these instruments.
Numerous data suggest that the physical examination and medical history of COPD patients are ineffective for diagnosing mild to moderate obstructive ventilatory deficits. As a result, a comprehensive pulmonary function test provides the most accurate assessment of lung impairment in patients. Spirometry is an ideal test for the clinical diagnosis of COPD since it provides essential information at a low cost. Because spirometry can diagnose chronic obstructive pulmonary disease in its earliest stages, even before evident symptoms appear, the patients are anticipated to demand more spirometers in the coming years.
Asthma is among the most commonly diagnosed non-communicable diseases. It inflames and narrows the airways of the lungs and is characterized by bouts of shortness of breath and wheezing that vary in frequency and intensity from case to case. Asthma cannot be cured, but early diagnosis and treatment can control the disease and allow for a high quality of life. As spirometers aid in the detection and diagnosis of asthma to a greater extent, a rise in asthma prevalence among the population is expected to drive demand for spirometers.
Based on end-user, the market is bifurcated into hospitals & clinics, home care settings, and others.
Hospitals & clinics are expected to grow enormous market share with the highest CAGR of 3.9% during the forecast period. Hospitals are health care facilities with trained medical and nursing personnel and advanced diagnostic equipment for identifying respiratory disorders. Clinics, on the other hand, can exist either within a hospital or as an independent institutions outside of a hospital. Most patients prefer hospital & clinic care for respiratory disorders due to their benefits over other facilities. These include the availability of modern pulmonary function testing devices, such as spirometers, skilled medical technicians, accurate test findings, and payment for completed tests. Consequently, increased patient preference for respiratory treatments in hospitals and clinics will likely drive spirometer market growth throughout the forecast period.
Homecare settings are anticipated to have the second-largest market share. The advent of home-based spirometers makes it possible for patients to perform the test in the comfort of their own homes. Though conducting pulmonary function tests at home might be difficult for first-time users, manufacturers are creating modern, portable, and user-friendly spirometers for homecare settings that do not need professionals. Thus, home-based spirometers reduce patient trips to clinics or hospitals and expedite their return to a normal lifestyle.